Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
NEW YORK - Moolec Science Limited, a subsidiary of Moolec Science SA (NASDAQ:MLEC), a $27.47 million market cap biotechnology company, has received a Notice of Allowance from the United States Patent and Trademark Office for its Piggy Sooy technology, according to a press release statement issued Wednesday. While the company has shown impressive revenue growth of 170% in the last twelve months, InvestingPro data reveals significant challenges in maintaining profitability.
The patented technology enables soybeans to express porcine hemeproteins in their seeds. The patent covers the plants, seeds, development methods, and resulting food compositions, providing Moolec with exclusive commercial rights in the U.S. until 2042.
This development follows the April 2024 determination by the USDA-APHIS that Piggy Sooy does not present plant pest risks different from conventional soybeans, exempting it from regulation under 7 CFR part 340.
According to the company’s Chief Science Officer, Amit Dhingra, initial field trials showed over 20% animal protein content in the total soluble protein fraction. The company claims one acre of these modified soybeans can produce the same amount of protein as approximately 10 pigs, while using significantly less land, water, and generating fewer carbon emissions.
The patent is part of Moolec’s broader intellectual property strategy, with over fifteen patent applications filed globally to protect its Molecular Farming innovations.
Moolec Science describes itself as a food ingredient company focused on producing animal proteins and nutritional oils in plants through molecular farming techniques.
In other recent news, Moolec Science SA has announced the approval of a Business Combination Agreement (BCA) with several entities, including Bioceres Group and Union Group, following a shareholder vote at an Extraordinary General Meeting. This move is expected to advance the strategic transactions outlined in the agreement. Additionally, Moolec Science disclosed a 1-for-10 reverse stock split, effective May 14, 2025, aimed at consolidating shares to potentially enhance marketability and liquidity. This structural change will reduce the number of outstanding shares from approximately 40 million to 4 million. Shareholders have also approved a redomiciliation of the company to the Cayman Islands and authorized a capital increase of $5 billion. Furthermore, Moolec Science received a compliance extension from the Nasdaq Hearings Panel, requiring a reverse stock split to maintain its listing status. Failure to meet Nasdaq’s conditions by May 30, 2025, could result in delisting. The company continues to navigate these strategic and compliance-related changes under the leadership of CEO Gastón Paladini.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.